Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Nam	e of entity		ABN/ARSN
Sigi	ma Pharmaceuticals Limited		15 088 417 403
We	(the entity) give ASX the following	ng information.	
Inf	ormation about buy-back		
1	Type of buy-back	On-market buy-back	
2	Date Appendix 3C was given to ASXo	13 September 2012	
	. 1 . 6 . 11 . 1	ought back or in	relation to which
	tal of all shares/units be eptances have been receiv	_	
		_	
		ved, before, and on, Before previous	previous day
acc	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been	ved, before, and on, Before previous day	Previous day

		Before previous		Previous day			
		day					
5	If buy-back is an on-market buy-back	Highest \$0.8525	price	paid:	Highest \$0.8000	price	paid:
		Lowest	n #i n n	م د ظ	Lowest \$0.7850	price	paid:
		\$0.6250	price	paid:	Highest under \$0.8201	price al rule	lowed 7.33:

How many shares/units may still be bought back?

6	If the company/trust has	63.025.288
_	disclosed an intention to buy	
	back a maximum number of	
	shares/units - the remaining	
	number of shares/units to be	
	bought back	

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:	(Director/Company secretary)	Date: 14 June 2013
Print name: Su	ne Morgan	